Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia
Identifieur interne : 001895 ( Main/Exploration ); précédent : 001894; suivant : 001896Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia
Auteurs : A. Waladkhani [Allemagne]Source :
- European Journal of Cancer Care [ 0961-5423 ] ; 2004-09.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Clinical Trials as Topic, Filgrastim, Granulocyte Colony-Stimulating Factor (analogs & derivatives), Granulocyte Colony-Stimulating Factor (therapeutic use), Hematologic Agents (therapeutic use), Humans, Neoplasms (complications), Neoplasms (drug therapy), Neutropenia (chemically induced), Neutropenia (drug therapy), Neutropenia (prevention & control), Recombinant Proteins, Treatment Outcome, chemotherapy, filgrastim, granulocyte colony‐stimulating factors, neutropenia, pegfilgrastim.
- MESH :
- chemical , adverse effects : Antineoplastic Agents.
- chemical , analogs & derivatives : Granulocyte Colony-Stimulating Factor.
- chemical , therapeutic use : Granulocyte Colony-Stimulating Factor, Hematologic Agents.
- chemically induced : Neutropenia.
- complications : Neoplasms.
- drug therapy : Neoplasms, Neutropenia.
- prevention & control : Neutropenia.
- Clinical Trials as Topic, Filgrastim, Humans, Recombinant Proteins, Treatment Outcome.
Abstract
Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.
Url:
DOI: 10.1111/j.1365-2354.2004.00503.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001718
- to stream Istex, to step Curation: 001604
- to stream Istex, to step Checkpoint: 000965
- to stream PubMed, to step Corpus: 000735
- to stream PubMed, to step Curation: 000735
- to stream PubMed, to step Checkpoint: 000735
- to stream Ncbi, to step Merge: 000168
- to stream Ncbi, to step Curation: 000168
- to stream Ncbi, to step Checkpoint: 000168
- to stream Main, to step Merge: 001A86
- to stream Main, to step Curation: 001895
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title>
<author><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2D0503325A4D3C658F722C331719FB85571CE860</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1365-2354.2004.00503.x</idno>
<idno type="url">https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001718</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001718</idno>
<idno type="wicri:Area/Istex/Curation">001604</idno>
<idno type="wicri:Area/Istex/Checkpoint">000965</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000965</idno>
<idno type="wicri:doubleKey">0961-5423:2004:Waladkhani A:pegfilgrastim:a:recent</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15305906</idno>
<idno type="wicri:Area/PubMed/Corpus">000735</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000735</idno>
<idno type="wicri:Area/PubMed/Curation">000735</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000735</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000735</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000735</idno>
<idno type="wicri:Area/Ncbi/Merge">000168</idno>
<idno type="wicri:Area/Ncbi/Curation">000168</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000168</idno>
<idno type="wicri:doubleKey">0961-5423:2004:Waladkhani A:pegfilgrastim:a:recent</idno>
<idno type="wicri:Area/Main/Merge">001A86</idno>
<idno type="wicri:Area/Main/Curation">001895</idno>
<idno type="wicri:Area/Main/Exploration">001895</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title>
<author><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier</wicri:regionArea>
<wicri:noRegion>Trier</wicri:noRegion>
<wicri:noRegion>Trier</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Cancer Care</title>
<idno type="ISSN">0961-5423</idno>
<idno type="eISSN">1365-2354</idno>
<imprint><publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-09">2004-09</date>
<biblScope unit="volume">13</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="371">371</biblScope>
<biblScope unit="page" to="379">379</biblScope>
</imprint>
<idno type="ISSN">0961-5423</idno>
</series>
<idno type="istex">2D0503325A4D3C658F722C331719FB85571CE860</idno>
<idno type="DOI">10.1111/j.1365-2354.2004.00503.x</idno>
<idno type="ArticleID">ECC503</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0961-5423</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term>
<term>Clinical Trials as Topic</term>
<term>Filgrastim</term>
<term>Granulocyte Colony-Stimulating Factor (analogs & derivatives)</term>
<term>Granulocyte Colony-Stimulating Factor (therapeutic use)</term>
<term>Hematologic Agents (therapeutic use)</term>
<term>Humans</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neutropenia (chemically induced)</term>
<term>Neutropenia (drug therapy)</term>
<term>Neutropenia (prevention & control)</term>
<term>Recombinant Proteins</term>
<term>Treatment Outcome</term>
<term>chemotherapy</term>
<term>filgrastim</term>
<term>granulocyte colony‐stimulating factors</term>
<term>neutropenia</term>
<term>pegfilgrastim</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term>
<term>Hematologic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term>
<term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Filgrastim</term>
<term>Humans</term>
<term>Recombinant Proteins</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
</noRegion>
<name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001895 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001895 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Rhénanie |area= UnivTrevesV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:2D0503325A4D3C658F722C331719FB85571CE860 |texte= Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia }}
This area was generated with Dilib version V0.6.31. |